BR112014023483A2 - - Google Patents
Info
- Publication number
- BR112014023483A2 BR112014023483A2 BR112014023483A BR112014023483A BR112014023483A2 BR 112014023483 A2 BR112014023483 A2 BR 112014023483A2 BR 112014023483 A BR112014023483 A BR 112014023483A BR 112014023483 A BR112014023483 A BR 112014023483A BR 112014023483 A2 BR112014023483 A2 BR 112014023483A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614932P | 2012-03-23 | 2012-03-23 | |
| US61/614,932 | 2012-03-23 | ||
| PCT/US2013/031232 WO2013142236A1 (en) | 2012-03-23 | 2013-03-14 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014023483A2 true BR112014023483A2 (enExample) | 2017-06-20 |
| BR112014023483B1 BR112014023483B1 (pt) | 2022-05-10 |
Family
ID=49223223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014023483-3A BR112014023483B1 (pt) | 2012-03-23 | 2013-03-14 | Composto e seu uso, composição farmacêutica e seu uso |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9914722B2 (enExample) |
| EP (1) | EP2828247B1 (enExample) |
| JP (1) | JP6219921B2 (enExample) |
| KR (1) | KR102109992B1 (enExample) |
| CN (1) | CN104470909B (enExample) |
| BR (1) | BR112014023483B1 (enExample) |
| CA (1) | CA2868026C (enExample) |
| EA (1) | EA028382B1 (enExample) |
| MX (1) | MX358514B (enExample) |
| WO (1) | WO2013142236A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47689E1 (en) | 2011-12-30 | 2019-11-05 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| ES2733644T3 (es) | 2012-01-26 | 2019-12-02 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| JP6092897B2 (ja) | 2012-02-10 | 2017-03-08 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| EA029155B1 (ru) | 2012-03-01 | 2018-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| MX2015008146A (es) * | 2012-12-24 | 2016-01-20 | Univ Ramot | Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas. |
| CN105392790B (zh) | 2013-08-19 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途 |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| KR20180019234A (ko) | 2015-06-26 | 2018-02-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체 |
| WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| CN110946865B (zh) | 2015-12-10 | 2024-01-26 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| WO2018098446A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc | Methods for modulating rna splicing |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| BR112019026508A2 (pt) | 2017-06-14 | 2020-07-14 | Ptc Therapeutics, Inc. | métodos para modificar o splicing do rna |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| RU2020105929A (ru) | 2017-08-04 | 2021-09-06 | Скайхоук Терапьютикс, Инк. | Способы и композиции для модулирования сплайсинга |
| JPWO2019168170A1 (ja) * | 2018-03-02 | 2021-03-04 | 国立大学法人 長崎大学 | クロモン誘導体及びアミロイド関連疾患診断用組成物 |
| JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| CA3105174A1 (en) | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| JP7603592B2 (ja) | 2019-02-05 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| EP3920926A4 (en) | 2019-02-05 | 2022-10-19 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN119638696A (zh) | 2019-02-06 | 2025-03-18 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| KR102823820B1 (ko) * | 2022-09-01 | 2025-06-23 | 단국대학교 천안캠퍼스 산학협력단 | 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
| WO2024249554A1 (en) * | 2023-05-30 | 2024-12-05 | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | Multitarget small molecule inhibitors and uses thereof |
| CN121488042A (zh) * | 2023-06-09 | 2026-02-06 | 豪夫迈·罗氏有限公司 | 诱导型基因表达系统 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH479607A (de) * | 1967-02-27 | 1969-10-15 | Geigy Ag J R | Verfahren zur Herstellung von Areno-oxazinonverbindungen |
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| GB1296469A (enExample) * | 1970-02-05 | 1972-11-15 | ||
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5599816A (en) | 1990-05-02 | 1997-02-04 | Abbott Laboratories | Quinolizinone type compounds |
| US5278174A (en) * | 1990-06-04 | 1994-01-11 | Scios Nova, Inc. | Sigma binding site agents |
| EP0640083A1 (en) | 1992-05-13 | 1995-03-01 | E.I. Du Pont De Nemours And Company | Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides |
| EP0625522B1 (en) * | 1993-05-18 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Benzopyran derivatives and their use |
| US5597922A (en) | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
| HK1040076A1 (zh) | 1998-09-21 | 2002-05-24 | 希雷生物化学有限公司 | 作为整联蛋白抑制剂的喹嗪酮 |
| AU2001230426C1 (en) | 2000-01-24 | 2006-06-22 | Astrazeneca Ab | Therapeutic morpholino-substituted compounds |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| US20040077529A1 (en) | 2002-06-10 | 2004-04-22 | Per-Fredrik Lehmann | Urotensin II receptor agents |
| NZ538420A (en) | 2002-08-16 | 2007-06-29 | Kinacia Pty Ltd | Inhibition of phosphoinositide 3-kinase beta |
| CN101260104A (zh) * | 2002-08-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
| AU2003298719A1 (en) * | 2002-11-25 | 2004-06-18 | Antonia C. Kaloidis | Treatment for sma disease |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| WO2004113335A2 (en) | 2003-06-20 | 2004-12-29 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| EP1687002A4 (en) | 2003-11-10 | 2008-07-23 | Synta Pharmaceuticals Corp | CONDENSED HETEROCYCLIC COMPOUNDS |
| BRPI0510560A (pt) | 2004-05-04 | 2007-11-20 | Warner Lambert Co | pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos |
| US7846915B2 (en) | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| WO2006078834A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| WO2006082245A1 (en) * | 2005-02-07 | 2006-08-10 | Novo Nordisk A/S | Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand |
| US8410109B2 (en) * | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| ES2539828T3 (es) | 2007-09-14 | 2015-07-06 | Naturewise Biotech & Medicals Corporation | Compuestos para la inhibición de la histona de acetilasa |
| US8008344B2 (en) | 2007-09-14 | 2011-08-30 | NatureWise Biotech and Medicals Corporation | Compounds for the inhibition of histone deacetylase |
| JP2011513342A (ja) | 2008-03-06 | 2011-04-28 | ロッタファルム・ソシエタ・ペル・アチオニ | 関節炎、癌および関連疼痛の治療のための２−アリールおよび２−ヘテロアリール４ｈ−１−ベンゾピラン−４−オン−６−アミジノ誘導体 |
| US8633019B2 (en) * | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| US20120010178A1 (en) * | 2008-10-21 | 2012-01-12 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
| CN101851220A (zh) * | 2009-04-03 | 2010-10-06 | 彦臣生技药品股份有限公司 | 异戊二烯类黄酮化合物及其用途 |
| DK2493871T3 (da) * | 2009-10-30 | 2014-11-10 | Prestwick Chemical Sas | Nye oximderivater samt deres anvendelse som allosteriske modulatorer af metabotropiske glutamatreceptorer |
| PT2496567T (pt) * | 2009-11-05 | 2017-11-15 | Rhizen Pharmaceuticals S A | Novos moduladores de quinase benzopiran |
| US8754220B2 (en) | 2009-11-20 | 2014-06-17 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide M1 receptor positive allosteric modulators |
| CN102812023A (zh) | 2010-01-13 | 2012-12-05 | 韩国巴斯德研究所 | 抗感染吡啶并(1,2-a)嘧啶类 |
| WO2011130515A1 (en) | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| RS58326B1 (sr) * | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Nova jedinjenja kao modulatori proteinskih kinaza |
| USRE47689E1 (en) | 2011-12-30 | 2019-11-05 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| ES2733644T3 (es) | 2012-01-26 | 2019-12-02 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| JP6092897B2 (ja) | 2012-02-10 | 2017-03-08 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| EA029155B1 (ru) | 2012-03-01 | 2018-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
-
2013
- 2013-03-14 CA CA2868026A patent/CA2868026C/en active Active
- 2013-03-14 US US14/386,524 patent/US9914722B2/en active Active
- 2013-03-14 CN CN201380027139.9A patent/CN104470909B/zh active Active
- 2013-03-14 BR BR112014023483-3A patent/BR112014023483B1/pt active IP Right Grant
- 2013-03-14 JP JP2015503291A patent/JP6219921B2/ja active Active
- 2013-03-14 MX MX2014011233A patent/MX358514B/es active IP Right Grant
- 2013-03-14 KR KR1020147029409A patent/KR102109992B1/ko active Active
- 2013-03-14 WO PCT/US2013/031232 patent/WO2013142236A1/en not_active Ceased
- 2013-03-14 EP EP13763520.7A patent/EP2828247B1/en active Active
- 2013-03-14 EA EA201491766A patent/EA028382B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2828247B1 (en) | 2019-01-16 |
| MX2014011233A (es) | 2014-11-25 |
| CN104470909A (zh) | 2015-03-25 |
| EA028382B1 (ru) | 2017-11-30 |
| EP2828247A1 (en) | 2015-01-28 |
| JP6219921B2 (ja) | 2017-10-25 |
| HK1202527A1 (en) | 2015-10-02 |
| BR112014023483B1 (pt) | 2022-05-10 |
| EA201491766A1 (ru) | 2015-03-31 |
| CA2868026A1 (en) | 2013-09-26 |
| JP2015517988A (ja) | 2015-06-25 |
| MX358514B (es) | 2018-08-24 |
| EP2828247A4 (en) | 2015-12-16 |
| KR20140135840A (ko) | 2014-11-26 |
| US20150080383A1 (en) | 2015-03-19 |
| CN104470909B (zh) | 2018-04-24 |
| KR102109992B1 (ko) | 2020-05-13 |
| WO2013142236A1 (en) | 2013-09-26 |
| US9914722B2 (en) | 2018-03-13 |
| CA2868026C (en) | 2021-02-16 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 311/00 , A01N 43/16 , A61K 31/35 Ipc: C07D 311/00 (2006.01), C07D 487/04 (2006.01), C07D |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2013, OBSERVADAS AS CONDICOES LEGAIS |